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We reﬂ   ect on remarkable accomplishments in global 
tuberculosis (TB) control and identify persistent obstacles to 
the successful elimination of TB from the United States and 
globally. One hundred and twenty nine years after Koch’s 
discovery of the etiologic agent of TB, this health scourge 
continues to account for 9.4 million cases and 1.7 million 
deaths annually worldwide. Implementation of the Directly 
Observed Treatment Short-course strategy from 1995 through 
2009 has saved 6 million lives. TB control is increasingly 
being achieved in countries with high-income economies, yet 
TB continues to plague persons living in countries with low-
income and lower-middle–income economies. To accelerate 
progress against the global effects of disease caused by TB 
and achieve its elimination, we must bridge 3 key gaps in 
implementation, knowledge, and ambition.
A
s we commemorate World Tuberculosis (TB) 
Day, March 24, we pause to reﬂ  ect on remarkable 
accomplishments in eliminating TB in the United States 
and other parts of the world and to identify persistent 
obstacles to its eventual elimination. World TB Day marks 
the day when, in 1882, Robert Koch delivered his lecture to 
the Physiologic Society of Berlin announcing the discovery 
of the tubercle bacillus as the etiologic agent of TB (1). 
At the time, TB was estimated to account for one ﬁ  fth to 
one fourth of all deaths in Europe. One hundred twenty-
nine years later, TB is increasingly under control in most 
countries with high-income economies (2) yet continues 
to afﬂ  ict persons living in countries with low-income and 
lower-middle–income economies (3,4). The World Health 
Organization (WHO) reported an estimated 9.4 million 
incident TB cases and 1.7 million deaths in 2009. Existing 
evidence-based interventions for TB control that have been 
successfully implemented from 1995 through 2009 have 
saved 6 million lives and alleviated much human suffering 
(3). Yet, by 2009 only an estimated 63% of annual incident 
TB cases were being detected and reported; of these, 86% 
were successfully treated (3). To accelerate progress against 
the global effect of disease caused by TB and to achieve its 
elimination, we must bridge 3 key gaps in implementation, 
knowledge, and ambition.
Implementation Gap
In his 1963 lecture delivered at the Postgraduate 
Medical School in London, Wallace Fox observed that 
remarkable progress in the chemotherapy of TB had 
been achieved over the prior decade “in the technically 
advanced countries” (5). In contrast, he remarked that 
nonindustrialized countries “have derived very little beneﬁ  t 
from the progress.” Fox cited 2 reasons for this lack of 
progress: a shortage of medical resources and “little attempt 
to adapt present knowledge to their speciﬁ  c problems” (5). 
During Fendall’s 1972 presentation at the Symposium on 
the Teaching of Teaching Tropical Medicine, an epitaph 
is suggested to describe medicine throughout the 20th 
century: “Brilliant in its scientiﬁ  c discoveries, superb in 
its technological breakthroughs, but woefully inept in 
its application of knowledge to those most in need” (6). 
Fendall further suggested “all that remains is the problem 
of translating what is current common knowledge and 
routine medical and health practice to the other two thirds 
of the world: the ‘implementation gap’ must be closed.”
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Globally, this implementation gap has been closing as 
a result of reliance on the evidence-based strategy for TB 
control, originally known as Directly Observed Treatment 
Short-course (DOTS). This strategy was initially based 
on diagnostic and treatment recommendations derived 
from randomized controlled trials, conducted largely 
by the British Medical Research Council (7) and the US 
Public Health Service, which established the efﬁ  cacy and 
safety of drugs against TB (8). Additionally, the basic 
elements of the strategy were deﬁ  ned and ﬁ  eld tested under 
mutual assistance programs between host countries and 
the International Union Against Tuberculosis and Lung 
Disease (9). The DOTS strategy was endorsed by consensus 
derived in technical advisory bodies and promulgated by 
WHO and the global Stop TB Partnership. Its widespread 
implementation has been more recently facilitated by 
resources from governments; the Global Fund for AIDS, 
Tuberculosis, and Malaria; and the President’s Emergency 
Plan for AIDS Relief (10–12). Furthermore, TB control has 
been demonstrated to be among the most cost effective of 
health interventions (13).
The original DOTS strategy contained 5 basic 
elements: 1) secure political commitment with adequate 
and sustained ﬁ   nancing; 2) ensure early case detection 
and diagnosis through quality-assured bacteriology; 3) 
provide standardized treatment with supervision and 
patient support; 4) ensure effective drug supply and 
management; and 5) monitor and evaluate performance and 
effects. This strategy has now been expanded to contain 
additional elements to confront other evolving needs, 
such as addressing HIV-associated TB, and multidrug-
resistant and extensively drug-resistant TB; contributing 
to strengthening health systems; engaging all providers 
(public, voluntary, and private) and affected communities; 
promoting use of the International Standards for TB Care; 
and enabling and promoting research (14,15).
The advances achieved with DOTS from 1995 through 
2009 include treating nearly 49 million persons and 
curing 41 million with TB, which was accompanied by a 
peak in global TB trends in 2004 followed by a relatively 
slow decline (3). These advances notwithstanding, TB 
continues to hold its dubious place as a leading infectious 
killer of young adults, and the disease preys on the most 
vulnerable persons in many parts of the globe (16). These 
populations are known to have difﬁ   culty in accessing 
available diagnostic tests and in obtaining curative short-
course therapeutic regimens that require >6 months of 
multiple drugs to achieve the desired outcomes. Even 
when all countries of the world have adopted policies 
consistent with the DOTS strategy, a sizable proportion of 
estimated cases (≈37%) are undetected, and those infected 
are likely not receiving optimal treatment regimens. Efforts 
must now focus on tackling social determinants of illness 
associated with TB by expanding and facilitating access to 
impoverished persons in densely populated urban areas and 
remote villages. 
In addition to partnering with all health providers (e.g., 
private, public, voluntary, traditional healers) to facilitate 
access to care, those concerned with public health must 
concentrate on subtleties such as optimizing the number of 
clinics or dispensaries offering diagnostic and therapeutic 
services, providing patient-convenient hours of operation, 
recognizing difﬁ  culties with distance and transportation, 
and minimizing out-of-pocket expenditures (including 
lost wages) for transportation, child care, and diagnostic 
services. An analysis from India has reported that 72% of 
TB patients who had a low standard of living (e.g., earning 
US $1–$2/d) ﬁ   rst saw private providers and spent, on 
average, $145 before starting treatment with the Revised 
National TB Program, thus documenting the devastating 
economic toll incurred by poor persons with TB (17). 
Engagement of affected communities will also prove 
crucial to create educated consumers of services. Public 
communication campaigns will help educate persons about 
the signs and symptoms of TB, provide information about 
where to access quality services and drugs, alleviate stigma, 
and create the demand for these basic health services from 
all providers of care and government decision-makers.
Other scientiﬁ  c advances that have lagged behind in 
implementation include the use of universal genotyping 
of Mycobacterium tuberculosis clinical isolates as a way 
to understand and interrupt chains of recent and ongoing 
transmission and the use of universal drug susceptibility 
testing with liquid culture media that reduce turn-around 
times by several weeks (available in the United States since 
1994) for timely surveillance of drug resistance trends 
and to guide optimal treatment regimens. Most recently, 
technologic advances have demonstrated the ability to rely 
on detection of bacterial DNA by PCR. The WHO policy 
recommendation to rely on Xpert MTB/RIF (Cepheid, 
Sunnyvale, CA, USA) for same-day diagnosis accentuates 
and magniﬁ  es this implementation gap (18).
A growing concern has to do with the gap in 
successfully addressing concurrent conditions associated 
with TB, such as HIV, diabetes, smoking, indoor air 
pollution, alcoholism, and malnutrition (16). This more 
holistic approach provides an ideal way to beneﬁ  t both 
individual and public health, and secondarily to strengthen 
health systems. When modeled after the basic principles 
that underpin TB control, the combined interventions will 
provide platforms for planning, service delivery, analysis, 
accountability, and corrective actions.
In the zeal to bridge the implementation gap, we must 
avoid past false dichotomies. There are those who see the way 
forward as limited to securing investments and channeling all 
resources to expand access to available diagnostic services 
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and curative drugs. Available tools are relatively blunt and 
limited, especially for effectively addressing HIV-associated 
TB and multidrug-resistant and extensively drug-resistant 
TB. In tackling urgent unmet needs, we must honestly 
acknowledge existing limitations and not ignore the need to 
bridge the immense knowledge gap in TB. Otherwise, we 
risk interventions that lack innovation, creativity, and do not 
keep pace with technological advances that could accelerate 
the path to elimination.
Knowledge Gap
There remain critical areas of collective ignorance 
with regard to M. tuberculosis. These include knowledge 
of rapid, simple, and inexpensive methods of detection; 
molecular mechanisms of resistance to chemotherapy; 
virulence; host defense correlates of susceptibility to and 
protection against the organism; and optimal targets for 
development of new antimicrobial drugs.
Until the past 2 decades, deﬁ  nitive detection of M. 
tuberculosis relied exclusively on culture, which takes 
weeks because of the requisite generation time of 18–24 
hours, giving rise to the apt descriptor of M. tuberculosis 
as “slow growing” bacteria. In low resource settings, even 
culture may not be available and diagnosis must be based 
on smear microscopy, which fails to detect nearly half of 
patients with TB (14). Advances in molecular biology and, 
ultimately, the sequencing of the M. tuberculosis genome 
led to rapid molecular methods of detection that, although 
reasonably accurate, were cumbersome and expensive 
(19,20). Only relatively recently has a promising new 
molecular diagnostic test become available, the Xpert TB/
RIF, that is both simple and accurate (21). However, even 
with concessionary pricing for low-income countries, cost 
still remains an issue. 
Similarly, detection of drug resistance almost solely 
relies on phenotypic culture-based methods. Here, also, 
advances in molecular biology are moving the ﬁ  eld forward, 
but the situation is more complex than for detection of 
the organism. Fortunately, for the most important anti-
TB drug, rifampin, >95% of resistance can be attributed 
to mutations in 1 gene, which has greatly simpliﬁ  ed 
the development of molecular tests to detect rifampin 
resistance (22). Commercial assays that use line-probe and 
molecular beacon technologies have been produced that 
are rapid and accurate (22,23). However, for other ﬁ  rst-line 
drugs (such as isoniazid and ethambutol) and second-line 
drugs, the molecular mechanisms of drug resistance have 
only been partially elucidated, inhibiting the development 
of rapid molecular assays for these drugs (24). Thus, there 
remains a heavy reliance on inefﬁ  cient and slow culture-
based phenotypic methods.
Virulence of M. tuberculosis, especially variation 
among strains, is also poorly understood. There is evidence 
suggesting some strains may result in higher rates of disease 
progression, treatment failure, and relapse (25). Identifying 
genetic markers of M. tuberculosis virulence would enable 
additional attention to be focused on patients infected with 
strains manifesting such markers and who are therefore at 
the greatest risk for poor outcomes.
Our lack of understanding of host defense correlates of 
susceptibility to and protection against M. tuberculosis has 
stymied progress in 2 key areas: vaccine development and 
prevention through treatment of latent TB. A vaccine that 
uses an attenuated strain of M. bovis (M. bovis BCG) has 
been available for nearly a century and is one of the most 
widely used vaccines in the world. Although the vaccine 
does offer substantial protection against dissemination 
of M. tuberculosis infection in children, it only provides 
modest and highly variable protection against TB in general 
(26,27). Clearly, more efﬁ  cacious and safe vaccines are 
needed; these are only likely to be produced through a 
better understanding of immunologic mechanisms and 
correlates of protection. A related knowledge gap is 
the lack of understanding of why only a small fraction 
(≈5%–10%) of persons infected with M. tuberculosis later 
exhibit disease (28). It is evident that immunocompromised 
persons (e.g., HIV infected or receiving tumor necrosis–α 
inhibitors) are at greater risk, but we have little knowledge 
of why certain persons with apparently healthy immune 
systems experience progression to illness (28). This results 
in treating 10–20 persons with latent TB for every 1 that 
will have the infection progress to disease. Given the length 
of optimal treatment (9 months) and potential toxicity 
(liver injury), this intervention is obviously suboptimal and 
could be made much more efﬁ  cient if it could be targeted to 
persons at the highest risk of becoming ill. Thus, there is a 
crucial need to ﬁ  nd genetic and immunologic markers that 
confer increased susceptibility to progression.
Standard TB treatment requires multiple drugs for 
>6 months’ duration (29). These drugs have multiple and 
overlapping toxicities. For drug-resistant TB, treatment 
consists of more toxic, less effective second-line drugs 
that must be taken for 18–24 months (29). Some patients 
with extensively drug-resistant TB have been described 
as having run out of realistic therapeutic options and thus 
resemble TB patients in the pre–antimicrobial drug era. 
Additionally, persons with latent TB who are not ill tend 
to have a difﬁ  cult time completing the 9 months required 
for isoniazid treatment (previously described as preventive 
therapy or chemoprophylaxis). Safe and effective regimens 
that could be administered intermittently and/or within 3 
months are under study and show promise (30). All these 
factors underscore the need for new medications that are 
better tolerated and can produce a cure in less time. Given 
that drug toxicity and resistance are often class effects, 
development of new classes of anti-TB drugs is another 
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essential research need. Such development, in turn, will 
likely require identiﬁ  cation of new and better drug targets.
Although the knowledge and implementation gaps 
must be bridged, simply rectifying these inadequacies is 
insufﬁ   cient for elimination of TB. Societal resolve and 
ambition are also required to garner the necessary resources 
for sustained efforts and effective programs, adapted to 
local epidemiologic realities.
Ambition Gap
The report from the 1959 Arden House Conference 
on TB made a daring statement, possibly well ahead of its 
time, indicating that TB control “has progressed to the point 
where virtual elimination of the disease as a public health 
problem appears to be within reach” (31). However, it was 
not until 3 decades later that the Centers for Disease Control 
published a formal consensus plan for the elimination of 
TB in the United States (32). This plan was ambitious, 
yet initially naive about the full extent of the effects on 
TB incidence due to HIV infection; multidrug resistance; 
institutional transmission of M. tuberculosis; and the time 
lag for the development of new technologies for more 
effective prevention, prompt diagnosis and detection of 
drug resistance, and superior treatment of TB. These various 
factors converged to produce the unprecedented resurgence 
of TB experienced in the United States during 1985–1992 
(33). The rapid dissemination of multidrug-resistant TB 
among HIV-infected persons and their caregivers was 
accompanied by unacceptably high mortality rates and 
served as a clarion call to elicit concerted efforts and 
mobilize new resources to implement the 1992 National 
Action Plan to Combat Multidrug Resistant TB (34). The 
US Federal TB task force coordinated interagency work 
and successfully worked with health department-based 
TB programs across the nation to reverse this trend over 
ensuing years. In 2000, the Institute of Medicine reafﬁ  rmed 
the goal of TB elimination and recommended additional 
steps required for accelerated progress, including the need 
to commit to elimination as a national goal and to monitor 
progress (35).
In recent years, the risk of renewed complacency, 
resource limitations experienced by local health 
departments, and the direct effects of global TB on US 
disease rates (nearly 60% of incident TB cases reported in 
the United States in 2009 occurred in foreign-born persons) 
challenges advances to TB elimination in the near future. 
Bold ambition and expectations with sustained actions are a 
requisite to successfully eliminating TB in the United States 
and globally. The report of the 1997 Dahlem Workshop 
on the Eradication of Infectious Diseases recognizes that 
“[t]he success of any disease eradication initiative depends 
strongly on the level of societal and political commitment… 
Elimination and eradication are the ultimate goals of public 
health, evolving naturally from disease control. The basic 
question is whether these goals are to be achieved in the 
present or some future generation” (36).
Smallpox is the only infectious disease in humans 
that has been successfully eradicated, and this was only 
achieved by a campaign characterized by global solidarity 
in planning, collaboration, and concerted action. Few 
other infectious diseases meet the conditions that favor 
elimination or eradication (36). For the ﬁ  rst time in history, 
the international community has developed an impressive 
plan to eliminate global TB (14). We must seize this 
opportunity to make added and continued progress against 
this global health scourge. A nonconformist stance must 
prevail until TB is eliminated. This frame of mind was aptly 
recognized in 1963 by William Brown, who advocated 
for syphilis eradication during the 1960s. He argued 
that diseases targeted for eradication (or elimination) 
should attain a “status of intolerability” by both health 
authorities and the public, such that any occurrence of the 
disease, “no matter how small,” gives cause for immediate 
action (37). Public clamor would help ensure sustained 
political commitment and ongoing work. With relatively 
few exceptions, this sense of bold ambition has not 
characterized those working in TB prevention and control 
programs. A sense of impoverished will tends to afﬂ  ict 
those who work in resource-limited settings. And, to add 
insult to injury, there is a natural human propensity toward 
complacency when progress is being made and a disease 
is perceived to be under control. Attention and resources 
risk being diverted to address other pressing health needs. 
A 1962 Time Magazine article on syphilis resurgence and 
prospects for eradication demonstrates Dr Brown’s full 
grasp of this reality when he stated: “As a program for the 
control of a disease approaches the end point, meaning 
eradication, it is not the disease but the program that is the 
more likely to be eradicated” (38).
Clearly, we must boldly aspire to achieve the 
elimination of TB and commit to making it a reality in 
the United States and throughout the globe. Bridging all 3 
gaps in implementation, knowledge, and ambition should 
become mutually reinforcing to achieve the desired results. 
Dr Castro is director, Division of Tuberculosis Elimination, 
National Center for HIV, Viral Hepatitis, STD, and TB Prevention, 
and Commanding Flag Ofﬁ  cer, Commissioned Corps, Centers for 
Disease Control and Prevention and Agency for Disease Registry 
and Toxic Substances. He is also a member of the editorial board 
of Emerging Infectious Diseases. His research interests include 
the epidemiology, transmission dynamics, and clinical diagnostic 
trials of TB, multidrug-resistant and extensively drug-resistant 
TB, and HIV-related TB.
340  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011Bridging Gaps to Eliminate Tuberculosis
Dr LoBue is associate director for science in the Division 
of Tuberculosis and Elimination, National Center for HIV, Viral 
Hepatitis, STD, and TB Prevention, Centers for Disease Control 
and Prevention. His research interests include tuberculosis 
epidemiology, transmission dynamics, drug resistance, new 
diagnostics and new treatments.
References
  1.   Koch  R.  Die  Aetiologie  der  Tuberculose:  Berliner Klinische 
Wochenschrift 1882;19:221–30. Pinner B, Pinner M, translators. Am 
Rev Tuberc. 1932;25:298–323.
  2.   The World Bank. Country and Lending Groups [cited 2011 Jan 1]. 
http://data.worldbank.org/about/country-classifications/country-
and-lending-groups 
    3.   World Health Organization. Global tuberculosis control 2010 
[cited 2011 Jan 3]. http://whqlibdoc.who.int/publications/
2010/9789241564069_eng.pdf 
  4.   World Health Organization. Global tuberculosis control: a short up-
date to the 2009 report [cited 2011 Jan 3]. http://whqlibdoc.who.int/
publications/2009/9789241598866_eng.pdf 
    5.   Fox W. Realistic chemotherapeutic policies for tuberculosis in 
the developing countries. BMJ. 1964;1:135–42. DOI: 10.1136/
bmj.1.5376.135
  6.   Fendall NR. Auxiliaries and primary medical care. Bull N Y Acad 
Med. 1972;48:1291–300.
  7.   Fox W. Pillip Ellman Lecture: The modern management and therapy 
of pulmonary tuberculosis. Proc R Soc Med. 1977;70:4–15.
  8.   Mount FW, Ferebee SH. United States Public Health Service co-
operative investigation of antimicrobial therapy of tuberculosis. V: 
report on thirty-two week observations on combinations of isonia-
zid, streptomycin, and para-amino salicylic acid. Am Rev Tuberc. 
1954;70:521–6.
  9.   Rouillon A. The mutual assistance programme of the IUATLD. De-
velopment, contribution, and signiﬁ  cance. Bull Int Union Tuberc 
Lung Dis. 1991;66:159–72.
10.   Raviglione MC, Uplekar M. WHO’s new Stop TB strategy. Lancet. 
2006;367:952–5. DOI: 10.1016/S0140-6736(06)68392-X
11.   Komatsu R, Low-Beer D, Schwartlander B. Global Fund supported 
programmes’ contribution to international targets and the Millen-
nium Development Goals: an initial analysis. Bull World Health 
Organ. 2007;85:805–11. DOI: 10.2471/BLT.06.038315
12.   Coggin WL, Ryan CA, Holmes CB. Role of the US President’s 
emergency plan for AIDS relief in responding to tuberculosis and 
HIV coinfection. Clin Infect Dis. 2010;50(Suppl 3):S255–9. DOI: 
10.1086/651499
13.   Laxminarayan R, Klein EY, Adeyi O. Global investments in TB con-
trol: economic beneﬁ  ts. Health Aff (Millwood). 2009;28:w730–42. 
DOI: 10.1377/hlthaff.28.4.w730
14.   World Health Organization. The global plan to stop TB 2011–2015: 
transforming the ﬁ  ght towards the elimination of tuberculosis [cited 
2011 Jan 3]. http://www.stoptb.org/assets/documents/global/plan/
TB_GlobalPlanToStopTB2011-2015.pdf
15.   Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. In-
ternational standards for tuberculosis care. Lancet Infect Dis. 
2006;6:710–25. DOI: 10.1016/S1473-3099(06)70628-4
16.    Lönnroth K, Castro KG, Chakayah JM, Chauhan LS, Floyd K, 
Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, 
care, and social development. Lancet. 2010;375:1814–29. DOI: 
10.1016/S0140-6736(10)60483-7
17.   Pantoja A, Floyd K, Unnikrishnan KP, Jitendra R, Padma MR, Lal 
SS, et al. Economic evaluation of public–private mix for tuberculo-
sis care and control, India. Part I. Socio-economic proﬁ  le and costs 
among tuberculosis patients. Int J Tuberc Lung Dis. 2009;13:698–
704.
18.   World Health Organization. WHO endorses new rapid tuberculo-
sis test. 2010 [cited 2011 Jan 5]. http://www.who.int/tb/features_
archive/new_rapid_test/en/index.html 
19.   Greco S, Girardi E, Navarra A, Saltini C. Current evidence on di-
agnostic accuracy of commercially based nucleic acid ampliﬁ  ca-
tion tests for the diagnosis of pulmonary tuberculosis. Thorax. 
2006;61:783–90. DOI: 10.1136/thx.2005.054908
20   Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid 
ampliﬁ  cation tests for diagnosis of pulmonary tuberculosis in respi-
ratory specimens: meta-analysis and meta-regression. PLoS ONE 
2008;3:e1536. 
21.   Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp 
F, et al. Rapid molecular detection of tuberculosis and rifampin 
resistance. N Engl J Med. 2010;363:1005–15. DOI: 10.1056/
NEJMoa0907847
22.   Ramaswamy S, Musser JM. Molecular genetic basis of antimicro-
bial agent resistance in Mycobacterium tuberculosis: 1998 update. 
Tuber Lung Dis. 1998;79:3–29. DOI: 10.1054/tuld.1998.0002
23.   Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid 
molecular screening for multidrug-resistant tuberculosis in a high-
volume public health laboratory in South Africa. Am J Respir Crit 
Care Med. 2008;177:787–92. DOI: 10.1164/rccm.200709-1436OC
24.   García de Viedma D. Rapid detection of resistance in Mycobac-
terium tuberculosis: a review discussing molecular approaches. 
Clin Microbiol Infect. 2003;9:349–59. DOI: 10.1046/j.1469-
0691.2003.00695.x
25.   Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, 
et al.; Tuberculosis Trials Consortium. Relapse associated with ac-
tive disease caused by Beijing strain of Mycobacterium tuberculosis. 
Emerg Infect Dis. 2009;15:1061–7. DOI: 10.3201/eid1507.081253
26.   Trunz BB, Fine P, Dye C. Effect of BCG vaccination on child-
hood tuberculous meningitis and miliary tuberculosis worldwide: 
a meta-analysis and assessment of cost-effectiveness. Lancet. 
2006;367:1173–80. DOI: 10.1016/S0140-6736(06)68507-3
27.   Brewer TF. Preventing tuberculosis with bacillus Calmette-
Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis. 
2000;31(Suppl 3):S64–7. DOI: 10.1086/314072
28.   American Thoracic Society, Centers for Disease Control and Pre-
vention. Targeted tuberculin testing and treatment of latent tubercu-
losis infection. Am J Respir Crit Care Med. 2000;161:S221–47.
29.   American Thoracic Society, Infectious Diseases Society of America, 
Centers for Disease Control and Prevention. Treatment of tuberculo-
sis. MMWR Recomm Rep. 2003;52(No. RR-11):1–77. 
30.   Sterling TR, Borisov AS, Shang N, Bliven-Sizemore E, Chaisson 
RE, Gordin F, et al. The PREVENT TB Study (TB Trials Consor-
tium Study 26) of 3 months of once-weekly rifapentine plus INH 
vs. 9 months of daily INH for treatment of latent TB infection: ﬁ  rst 
report of results of a multi-center, randomized clinical trial. Sym-
posium 44. The Union/CDC Late-breaker session on tuberculosis. 
41st UNION World Conference on Lung Health; Berlin, Germany; 
November 15, 2010.
31   The Arden House Conference on Tuberculosis. US Department of 
Health, Education, and Welfare, Public Health Service. Publication 
no. 784. Washington: US Government Printing Ofﬁ  ce; 1961.
32.   Centers for Disease Control. A strategic plan for the elimination of 
tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 
1989;38(S-3):1–25. 
33.   Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology 
of tuberculosis in the United States, 1985 through 1992. JAMA. 
1994;272:535–9. DOI: 10.1001/jama.272.7.535
34.   Tuberculosis Task Force. National action plan to combat multidrug 
resistant tuberculosis. MMWR Recomm Rep. 1992;41(RR-11):
1–48.
35.   Institute of Medicine. Ending neglect: the elimination of tubercu-
losis in the United States. Washington: National Academies Press; 
2000.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011  341PERSPECTIVE
36.  Dowdle WR. The principles of disease elimination and eradication. 
MMWR Morb Mortal Wkly Rep. 1999;48(Suppl 1):23–7. 
37.   Brown WJ. A plan for the eradication of syphilis. South Med J. 
1963;56:840–3.
38.   Time Magazine. Medicine: resurgent syphilis: it can be eradicat-
ed. 1962 [cited 2011 Jan 4]. http://www.time.com/time/magazine/
article/0,9171,827568,00.html 
Address for correspondence: Kenneth G. Castro, Centers for Disease 
Control and Prevention, 1600 Clifton Rd NE, Mailstop E10, Atlanta, GA 
30333, USA; email: kgc1@cdc.gov
342  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011
Use of trade names is for identiﬁ  cation only and does not 
imply endorsement by the Public Health Service or by the US 
Department of Health and Human Services.